{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:02:46Z","timestamp":1793865766477,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,17]]},"DOI":"10.7759\/cureus.45416","type":"journal-article","created":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T17:37:51Z","timestamp":1694972271000},"source":"Crossref","is-referenced-by-count":7,"title":["Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis"],"prefix":"10.7759","author":[{"given":"Sayan","family":"Malakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Kothalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Shamsul Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday C","family":"Ghoshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in ulcerative colitis; preliminary report on a therapeutic trial","volume":"2","author":"Truelove SC","year":"1954","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954, 2:375-8. 10.1136\/bmj.2.4884.375","journal-title":"Br Med J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i4.579","article-title":"Management of acute severe ulcerative colitis","volume":"5","author":"Kedia S","year":"2014","unstructured":"Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol. 2014, 5:579-88. 10.4291\/wjgp.v5.i4.579","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00338","article-title":"Comparable long-term outcomes of cyclosporine and infliximab in patients with steroid-refractory acute severe ulcerative colitis: a meta-analysis","volume":"6","author":"Szemes K","year":"2019","unstructured":"Szemes K, So\u00f3s A, Hegyi P, et al.. Comparable long-term outcomes of cyclosporine and infliximab in patients with steroid-refractory acute severe ulcerative colitis: a meta-analysis. Front Med (Lausanne). 2019, 6:338. 10.3389\/fmed.2019.00338","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2022.00128","article-title":"Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring. [PREPRINT]","author":"Kumar P","year":"2023","unstructured":"Kumar P, Vuyyuru SK, Das P, et al.. Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring. [PREPRINT]. Intest Res. 2023, 10.5217\/ir.2022.00128","journal-title":"Intest Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12278","article-title":"Surgical and medical treatment in patients with acute severe ulcerative colitis","volume":"16","author":"Fornaro R","year":"2015","unstructured":"Fornaro R, Caratto M, Barbruni G, et al.. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015, 16:558-67. 10.1111\/1751-2980.12278","journal-title":"J Dig Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein JA","year":"2021","unstructured":"Berinstein JA, Sheehan JL, Dias M, et al.. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol. 2021, 19:2112-20.e1. 10.1016\/j.cgh.2021.05.038","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)","volume":"61","author":"Travis SP","year":"2012","unstructured":"Travis SP, Schnell D, Krzeski P, et al.. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012, 61:535-42. 10.1136\/gutjnl-2011-300486","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik T","year":"2021","unstructured":"Kucharzik T, Ellul P, Greuter T, et al.. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021, 15:879-913. 10.1093\/ecco-jcc\/jjab052","journal-title":"J Crohns Colitis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.16.1.4","article-title":"Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment","volume":"16","author":"Park DI","year":"2018","unstructured":"Park DI, Hisamatsu T, Chen M, et al.. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res. 2018, 16:4-16. 10.5217\/ir.2018.16.1.4","journal-title":"Intest Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"Travis SP","year":"1996","unstructured":"Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut. 1996, 38:905-10. 10.1136\/gut.38.6.905","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al.. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017, 376:1723-36. 10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"Ecco guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine T","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al.. Ecco guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022, 16:2-17. 10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab087","article-title":"Tofacitinib in acute severe ulcerative colitis: case series and a systematic review","volume":"27","author":"Jena A","year":"2021","unstructured":"Jena A, Mishra S, Sachan A, Singh H, Singh AK, Sharma V. Tofacitinib in acute severe ulcerative colitis: case series and a systematic review. Inflamm Bowel Dis. 2021, 27:e101-3. 10.1093\/ibd\/izab087","journal-title":"Inflamm Bowel Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa157","article-title":"Tofacitinib in acute severe ulcerative colitis\u2014a real-world tertiary center experience","volume":"26","author":"Honap S","year":"2020","unstructured":"Honap S, Pavlidis P, Ray S, et al.. Tofacitinib in acute severe ulcerative colitis\u2014a real-world tertiary center experience. Inflamm Bowel Dis. 2020, 26:e147-9. 10.1093\/ibd\/izaa157","journal-title":"Inflamm Bowel Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa357","article-title":"High-dose rescue tofacitinib prevented inpatient colectomy in acute severe ulcerative colitis refractory to anti-TNF","volume":"27","author":"Sedano R","year":"2021","unstructured":"Sedano R, Jairath V. High-dose rescue tofacitinib prevented inpatient colectomy in acute severe ulcerative colitis refractory to anti-TNF. Inflamm Bowel Dis. 2021, 27:e59-60. 10.1093\/ibd\/izaa357","journal-title":"Inflamm Bowel Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort","volume":"54","author":"Uzzan M","year":"2021","unstructured":"Uzzan M, Bresteau C, Laharie D, et al.. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort. Aliment Pharmacol Ther. 2021, 54:312-9. 10.1111\/apt.16463","journal-title":"Aliment Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis","volume":"17","author":"Berinstein JA","year":"2019","unstructured":"Berinstein JA, Steiner CA, Regal RE, et al.. Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2019, 17:988-90.e1. 10.1016\/j.cgh.2018.11.022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.050","article-title":"Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis","volume":"19","author":"Deepak P","year":"2021","unstructured":"Deepak P, Alayo QA, Khatiwada A, et al.. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021, 19:1592-601.e3. 10.1016\/j.cgh.2020.06.050","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.30.3.167","article-title":"Pneumocystis jirovecii pneumonia after initiation of tofacitinib therapy in rheumatoid arthritis: case-based review","volume":"30","author":"Grigoropoulos I","year":"2019","unstructured":"Grigoropoulos I, Thomas K, Christoforou P, et al.. Pneumocystis jirovecii pneumonia after initiation of tofacitinib therapy in rheumatoid arthritis: case-based review. Mediterr J Rheumatol. 2019, 30:167-70. 10.31138\/mjr.30.3.167","journal-title":"Mediterr J Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-015-0025-y","article-title":"Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis","volume":"15","author":"Valenzuela F","year":"2015","unstructured":"Valenzuela F, Papp KA, Pariser D, et al.. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. BMC Dermatol. 2015, 15:8. 10.1186\/s12895-015-0025-y","journal-title":"BMC Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4690-z","article-title":"Cost of illness in inflammatory bowel disease","volume":"62","author":"Kamat N","year":"2017","unstructured":"Kamat N, Ganesh Pai C, Surulivel Rajan M, Kamath A. Cost of illness in inflammatory bowel disease. Dig Dis Sci. 2017, 62:2318-26. 10.1007\/s10620-017-4690-z","journal-title":"Dig Dis Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01254-x","article-title":"Cost-effectiveness analysis of tofacitinib compared with biologics in biologic-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan","volume":"41","author":"Kobayashi T","year":"2023","unstructured":"Kobayashi T, Hoshi M, Yuasa A, et al.. Cost-effectiveness analysis of tofacitinib compared with biologics in biologic-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics. 2023, 41:589-604. 10.1007\/s40273-023-01254-x","journal-title":"Pharmacoeconomics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/186295-tofacitinib-in-steroid-refractory-acute-severe-ulcerative-colitis-a-retrospective-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:23Z","timestamp":1707509123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/186295-tofacitinib-in-steroid-refractory-acute-severe-ulcerative-colitis-a-retrospective-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,17]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.45416","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,17]]}}}